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Abstract
 
Polyclonal CD4
 
1
 
 T cell activation is characteristic of spontaneous lupus. As a potential explana-
tion for this phenotype, we hypothesized that T cells from lupus-prone mice are intrinsically
hyperresponsive to stimulation with antigen, particularly to those peptide ligands having a low
affinity for the T cell receptor (TCR). To test this hypothesis, we backcrossed the 
 
a
 
 and 
 
b
 
chain genes of the AND TCR specific for amino acids 88–104 of pigeon cytochrome C (PCC)
 
to the Fas-intact MRL/Mp
 
1
 
Fas-lpr
 
 and to the H-2
 
k
 
–matched control backgrounds B10.BR and
CBA/CaJ (MRL.AND, B10.AND, and CBA.AND, respectively), and assessed naive CD4
 
1
 
TCR transgenic T cell activation in vitro after its encounter with cognate antigen and lower af-
finity altered peptide ligands (APLs). MRL.AND T cells, compared with control B10.AND
and CBA.AND cells, proliferated more when stimulated with agonist antigen. More strikingly,
MRL.AND T cells proliferated significantly more and produced more interleukin 2 when
stimulated with the APLs of PCC 88–104, having lower affinity for the transgenic TCR. These
results imply that one of the forces driving polyclonal activation of 
 
a/b
 
 T cells in lupus is an in-
trinsically heightened response to peptide antigen, particularly those with low affinity for the
TCR, independent of the nature of the antigen-presenting cell and degree of costimulation.
Key words: autoreactive T cells • autoimmunity • systemic lupus erythematosus • tolerance • 
murine lupus
 
Introduction
 
Activated CD4
 
1
 
 a/b
 
 T cells are necessary for the produc-
tion of high affinity, isotype-switched pathogenic autoanti-
bodies, and full disease penetrance in humans and mice
with spontaneous lupus (1, 2). Polyclonal CD4
 
1
 
 T cell acti-
vation is a hallmark of human and murine lupus (3), sug-
gesting a global defect in the maintenance of T cell toler-
ance to self; however, the mechanism(s) of activation of T
cells responsive to self-peptides in lupus are unknown, as
are the source(s) of such peptides and the precise events
leading to autoreactive CD4
 
1
 
 T cell–B cell collaboration
that appear critical for pathogenic autoantibody production.
 
Negative selection in the thymus appears intact in lupus-
prone mice (4), suggesting that relevant autoreactive T
cells are of low enough affinity to escape to the periphery,
where they must bypass normal tolerance mechanisms. T
cell tolerance in the periphery may be maintained at least
in part through the interaction of low affinity self-antigens
with autoreactive T cells, resulting in anergy (5). Whereas
peripheral T cell tolerance in lupus may be lost because of
abnormalities in self-antigen presentation or aberrant co-
stimulation, an intrinsic T cell abnormality in the ability to
respond to tolerogenic signals may also contribute. Indeed,
there is growing evidence that T cell activation is abnormal
in lupus. Studies in lupus-prone NZM mice have identi-
fied a locus on chromosome 7 associated with generalized
activation, increased proliferation, and reduced activation-
 
induced cell death (AICD)
 
1
 
 of CD4
 
1
 
 T cells (6). In addi-
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T Cell Activation in Lupus
 
tion, abnormalities in TCR signaling in human lupus T
cells have been identified (7, 8), although it is not clear if
these abnormalities contribute to the global T cell activa-
tion characteristic of the disease.
Since T cell tolerance in the periphery may be main-
tained by the interaction of self-antigens with low affinity
for the TCR, we hypothesized that naive CD4
 
1
 
 T cells in
lupus would be more likely than T cells from nonautoim-
mune individuals to become activated when stimulated
with such antigens. This would help explain the polyclonal
T cell activation characteristic of human and murine lupus.
Since it is difficult to study antigen-specific responses of
human lupus CD4
 
1
 
 T cells because of the heterogeneity of
human peripheral blood lymphocytes (9) and the potential
confounding effect of immunosuppressive therapy, we
chose to address our hypothesis using a mouse model in
which antigen specificity and the activation state of the T
cells could be rigorously controlled. To achieve this, we
backcrossed the 
 
a
 
 and 
 
b
 
 chain genes of the AND TCR
specific for amino acids 88–104 of the pigeon cytochrome
C (PCC) to the Fas-intact MRL/Mp
 
1
 
Fas-lpr
 
 (MRL/
 
1
 
Fas-lpr
 
)
and to the H-2
 
k
 
–matched control backgrounds B10.BR
and CBA/CaJ (MRL.AND, B10.AND, and CBA.AND,
respectively [references 10, 11]). Naive CD4
 
1
 
 TCR trans-
genic T cells from these mice were then stimulated in vitro
using either agonist peptide 88–104 of PCC or altered pep-
tide ligands (APLs) of PCC 88–104 having equivalent af-
finity for the selecting I-E
 
k
 
 molecules, but lower affinity for
the transgenic TCR (12, 13). Our results demonstrate that
naive CD4
 
1
 
 
 
T cells from lupus-prone mice compared with
controls are hyperproliferative, more readily enter the cell
cycle, have a higher probability of displaying an activated
phenotype, and secrete more IL-2, especially when stimu-
lated with low affinity antigens. These data imply that a
lower threshold for activation and/or a more vigorous re-
sponse to the same degree of TCR activation contributes
to the loss of peripheral T cell tolerance in lupus.
 
Materials and Methods
 
Mice.
 
AND transgenic mice, expressing an 
 
a/b
 
 TCR
(V
 
a
 
11
 
1
 
, V
 
b
 
3
 
1
 
) recognizing PCC, were originally provided on
the B10.BR background by S. Hedrick (University of California
at San Diego, San Diego, CA; reference 10). The transgenic V
 
a
 
and V
 
b
 
 chains, which cosegregated in our hands, were serially
backcrossed to the MRL/
 
1
 
Fas-lpr
 
 (MRL.AND) and to the H-2
 
k
 
–
matched control background B10.BR (B10.AND) for 
 
.
 
15 gen-
erations, and to the control H-2
 
k
 
 CBA/CaJ strain (CBA.AND)
for 
 
.
 
7 generations. The two control strains lack endogenous (vi-
ral) superantigens, products of murine mammary tumor viruses
(MMTVs), that bind the transgenic V
 
b
 
3 chain, with resultant
central deletion in the context of I-E (14). Levels of expression of
the transgenic V
 
a
 
 and V
 
b
 
 chains and the CD4 coreceptor were
equivalent among the three strains, as determined by flow cytom-
etry. Transgenic mice were maintained as heterozygotes, with
screening performed using the PCR of tail DNA as described
previously (11) and phenotypic confirmation by flow cytometry.
The animals were identically housed in specific pathogen-free fa-
cilities at the Yale Animal Resources Center.
 
T Cell Preparation.
 
Young (1–2-mo-old) age- and sex-
matched mice were used for purification of CD4
 
1
 
 T cells by neg-
ative selection to avoid preactivation of the cells before in vitro
stimulation. Splenocyte suspensions were first treated with RBC
lysing buffer and then passed through Ficoll-Paque™ lymphocyte
separation medium. Cell suspensions from lymph nodes were
prepared from
 
 
 
axillary, brachial, and mesenteric lymph nodes.
CD8
 
1
 
 T cells, B cells, and APCs were removed by labeling with
the following biotinylated antibodies: anti-CD8 (clone 53-6.7);
anti-CD45R/B220 (RA3-6B2); anti-CD16/32 (2.4G2); anti–
I-A
 
k
 
 (11-5.2); and anti-CD11b (M1-70) (all from BD PharMin-
gen). The cells were washed and then incubated with streptavidin
microbeads (Miltenyi Biotec) with magnetic removal by passage
through a column using the protocol of the manufacturer. The
purity of transgenic CD4
 
1
 
 T cells was consistently 
 
.
 
93%, as con-
firmed by flow cytometric analysis for cells that were CD4
 
1
 
 and
expressed both V
 
a
 
11
 
1
 
 and V
 
b
 
3
 
1
 
. Transgenic TCR density and
CD4 coreceptor density were equivalent among the three groups
(data not shown). Transgenic cells were also 
 
.
 
93% naive as de-
termined by surface markers, CD44
 
low
 
, and CD62L
 
hi
 
 (15). To
ensure that only transgenic cells were included in our analyses,
CD4
 
1
 
V
 
a
 
11
 
hi
 
 cells were gated on for studies of activation marker
expression and division of individual cells (16). The percentage of
transgenic CD4
 
1
 
V
 
a
 
11
 
1
 
V
 
b
 
3
 
1
 
 T cells in the periphery was not
different among the three strains.
 
Flow Cytometric Analysis.
 
The following antibodies were used
for flow cytometry: anti-CD44–FITC (Pgp-1); anti-CD62L–PE
(MEL-14); anti-CD4–Cychrome (H219.19); biotinylated and
FITC–anti-V
 
a
 
11 (RR8-1); anti-V
 
b
 
3–PE (KJ25); and streptavi-
din-APC (BD PharMingen). Fluorescence analysis was done us-
ing a FACSCalibur™
 
 
 
flow cytometer using CELLQuest™ soft-
ware (Becton Dickinson).
 
T Cell Stimulation Assays.
 
TCR transgenic CD4
 
1
 
 T cells
(10
 
5
 
 cells) were cultured in 96-well round bottomed tissue cul-
ture plates in Click’s medium containing 10% FCS, 0.2 mM
glutamine, 100 U/ml penicillin, and 100 
 
m
 
g/ml streptomycin. T
cells were stimulated either with the dominant agonist peptide of
PCC (PCC 88–104) KAERADLIAYLKQATAK (peptide purity
 
.
 
90% by HPLC analysis; American Peptide Company) or with
APLs of PCC 88–104. These APLs differed from PCC 88–104
by either glutamine (K99Q), arginine (K99R), or isoleucine
(A96I) substitutions for lysine at position 99 and alanine at posi-
tion 96, respectively (peptide purity 
 
.
 
90%; Keck Foundation
Biomedical Resource Laboratory, Yale University). A96I, K99R,
and K99Q are well studied as APLs of the AND transgenic TCR.
A96I is an agonist for AND T cells in the C57BL background
(AND T cells are positively selected on either H-2
 
k
 
 or H-2
 
b
 
backgrounds; references 13, 17–19). K99Q functions as a weak
antagonist, with minimal evidence of TCR engagement and IL-2
production due to decreased affinity of the K99Q-MHC com-
plex for the PCC-specific TCR (12, 13). K99R is an antagonist
for the AD10 TCR transgene which also recognizes PCC (18).
A96I, K99Q, and K99R bind to I-E
 
k
 
 
approximately as well as the
agonist peptide PCC 88–104; the relative binding of A96I and
K99R to the AND TCR is unknown.
CH27 B lymphoblastoid cells (provided by Dr. C. Janeway,
Jr., Yale School of Medicine) expressing I-E
 
k
 
, B7.1, and B7.2
(20) were used as APCs and confirmed by flow cytometry to ex-
press these surface molecules. T cells were cocultured for 72 h
with mitomycin C–treated APCs (APC/T ratio 2:1) at 37
 
8
 
C.
Non–TCR-mediated proliferation was induced by culture with
10 ng/ml PMA (Sigma-Aldrich) and 500 ng/ml ionomycin (Cal-
biochem). [
 
3
 
H]Thymidine was added 18 h before harvesting. For 
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some experiments, T cells were labeled with the intracellular flu-
orescent dye 5,6-carboxyfluorescein diacetate succinimidyl ester
(CFSE) to determine their proliferative history after in vitro acti-
vation (21). T cells (5–10 
 
3
 
 10
 
6
 
/200 
 
m
 
l PBS) were labeled with 5
 
m
 
M CFSE for 10 min at room temperature. Unbound CFSE was
quenched by the addition of 500 
 
m
 
l of fetal bovine serum (21).
Transgenic cells were identified by gating on CD4
 
1
 
V
 
a
 
11
 
hi
 
 cells
(16). In some experiments, propidium iodide (PI) staining was
used to differentiate between living and dead transgenic T cells
after gating on CD4
 
1
 
V
 
a
 
11
 
hi
 
 cells.
 
Cytokine Production.
 
IL-2 production by transgenic T cells
was quantified by indirect ELISA of culture supernatants 24 h af-
ter stimulation in vitro using triplicate wells in 96-well round
bottomed plates. ELISA was performed according to established
methods using a murine IL-2 standard and antimurine IL-2 cap-
ture antibody (BD PharMingen). Background production of IL-2
seen with culture of T cells and APCs alone was similar among
the three test strains and was subtracted from the OD readings of
wells containing antigens to assess antigen-specific production of
IL-2. The production of IL-2 by transgenic T cells was also deter-
mined by intracellular cytokine staining using anti–IL-2–PE (BD
PharMingen) using the manufacturer’s recommended protocol.
The percentage of transgenic cells producing IL-2 was deter-
mined by gating on the CD4
 
1
 
V
 
a
 
11
 
hi
 
 population, as described
above.
 
Statistical Analysis.
 
Comparative data were analyzed using the
unpaired Student’s 
 
t 
 
test with two-tailed
 
 P 
 
value calculations us-
ing InStat software (GraphPad Software). Data shown are repre-
sentative of at least three separate experiments. Error bars indicate
SEM. Results of in vitro experiments are representative of three
separate experiments using two to three age- and sex-matched
animals in each group.
 
Results
 
We elected to use Fas-intact MRL/
 
1
 
Fas-lpr
 
 mice as the
experimental autoimmune strain for these studies. These
mice develop lupus and their use removed the confounding
effect of Fas deficiency on T cell activation and death
found in MRL/Fas
 
lpr
 
 mice (22) and avoids the CD4
 
2
 
CD8
 
2
 
(double negative) T cell population that accumulates in the
peripheral lymphoid organs of these latter animals, cells that
have defective responses to mitogens and are difficult to re-
move from in vitro assays.
 
MRL.AND TCR Transgenic T Cells Proliferate More in
Response to Agonist Peptide Than Control Transgenic T
Cells.
 
We initially studied the response of AND T cells to
peptide PCC 88–104, a known agonist of the AND TCR
(12, 18). Negatively selected naive AND T cells from the
spleens of 1–2-mo-old TCR transgenic mice were identi-
fied by flow cytometry as CD4
 
1
 
V
 
a
 
11
 
hi
 
 (16), and the num-
ber of cell divisions was estimated using the technique of
CFSE dilution. Using agonist PCC 88–104 antigen (0.05
 
m
 
M) presented by CH27 cells, there was a significant in-
crease in the mean number of cell divisions in MRL.AND
T cells 72 h later (Fig. 1 A). We also observed increased
proliferation at 72 h across a range of concentrations of
PCC 88–104 in a proliferation assay using [
 
3
 
H]thymidine
uptake (Fig. 1 B), with proliferation noted beginning at
0.001 
 
m
 
M.
 
To test whether the hyperresponsive phenotype of
MRL.AND T cells we observed with agonist peptide was
dependent on activation through the TCR, we measured
the proliferation of AND T cells stimulated with the mi-
togens PMA (10 ng/ml) and ionomycin (500 ng/ml).
MRL.AND T cells proliferated significantly more in re-
sponse to stimulation with PMA and ionomycin at 72 h
compared with control B10.AND and CBA.AND T cells
(Fig. 1 C).
 
AND TCR Transgenic T Cells Do Not Spontaneously Pro-
liferate and Are Not Spontaneously Activated In Vivo.
 
To in-
vestigate the possibility that any differences in cell division
observed in MRL.AND T cells were a consequence of ab-
errant cell function attributable to the expression of the
TCR transgene itself, and not due to the lupus genotype,
we studied the proliferation of negatively selected AND
TCR transgenic splenic T cells cultured either without
APCs or with unpulsed APCs. In our experimental system,
PCC-specific MRL.AND TCR transgenic T cells failed to
proliferate when cultured without APCs (data not shown).
Moreover, TCR transgenic T cells from all three strains
did not undergo cell division, as measured by CFSE dilu-
tion, to a significant degree without peptide stimulation
from APCs (see Fig. 3 A, data not shown). To further ad-
dress this question in a physiologic manner, we also asked if
there was spontaneous activation of transgenic T cells in
vivo. Here, we compared activation markers on splenic T
cells in both young (1–2-mo-old) and older (8–9-mo-old)
AND transgenic animals (Table I). Less than 2% of
B10.AND, CBA.AND, and MRL.AND TCR transgenic
T cells from young mice, and 
 
,
 
10% of AND T cells from
older mice, spontaneously (i.e.
 
,
 
 without immunization)
developed evidence of an activated phenotype in vivo
(CD44
 
hi
 
CD62Llo) or a phenotype of recent activation
(CD691CD251). These data establish that activation and
proliferation of AND TCR transgenic T cells are only seen
to a significant degree with stimulation by APCs plus pep-
tide antigen and are not a byproduct or artifact of the ex-
pression of the TCR itself.
MRL.AND TCR Transgenic T Cells Proliferate More in
Response to Low Affinity APLs of PCC Than Control TCR
Transgenic T Cells. We next studied the proliferative re-
sponse and activation of MRL.AND T cells to a previously
defined APL of the agonist peptide PCC 88–104 in which
glutamine is substituted for lysine at position 99 (K99Q;
reference 13). This peptide and native PCC 88–104 bind
equally well to I-Ek (12, 18), but the former peptide–MHC
complexes bind with z1/10 the affinity to the transgenic
TCR (12). Because of low affinity of the K99Q–MHC
complex for the TCR, naive mature peripheral CD41
AND T cells from nonautoimmune mice normally prolif-
erate poorly in response to this peptide and secrete minimal
amounts of IL-2, in contrast to the outcome after contact
with the cognate peptide PCC 88–104 (12, 18).
Naive AND T cells were stimulated with APL K99Q
presented by H-2k on CH27 cells at concentrations .100-
fold higher than is necessary to stimulate the cells with full
agonist peptide (13). MRL.AND T cells proliferated signif-332 T Cell Activation in Lupus
icantly more than B10.AND and CBA.AND T cells across
a range of concentrations of the K99Q peptide (P , 0.005;
Fig. 2 A). A different APL (A96I) yielded results similar to
K99Q (Fig. 2 B). To see if the hyperresponsive phenotype
to APL stimulation we observed in splenic T cells was also
true for lymph node T cells, we stimulated CD41 trans-
genic T cells from lymph nodes with varying concentra-
tions of the APL K99R presented by CH27 cells. Little to
no proliferation was noted in B10.AND and CBA.AND T
cells at the highest concentration of K99R tested (Fig. 2
C). In contrast, MRL.AND T cells proliferated .20-fold
more at the highest concentration of K99R. In addition,
MRL.AND T cells began to proliferate at three logs lower
concentration of K99R (0.1 mM) than needed to stimulate
control T cells. In concordance with these findings, there
was a striking difference in the effector phenotype of
splenic MRL.AND T cells compared with the other two
strains, with an approximately threefold increase in the per-
centage of activated CD44hi cells from the lupus back-
ground 48 h after stimulation with 25 mM K99Q (Fig. 2
D, middle; for comparison, the baseline phenotype of un-
stimulated cells is shown at the top). In comparison, there
was no significant difference in the percentage of activated
AND cells when stimulated with 0.05 mM agonist peptide
PCC 88–104 (Fig. 2 D, bottom).
MRL.AND T Cells Undergo More Cell Divisions in Re-
sponse to Stimulation with Low Affinity Ligands Than Nonauto-
immune AND T Cells. The differences in overall [3H]thy-
midine incorporation noted above with APL stimulation
Table I.  AND TCR Transgenic T Cells Are Not Spontaneously 
Activated In Vivo
Percentage
CD251
Percentage 
CD691
Percentage
activated
Young B10.AND 1.7 2.1 1.6
Young CBA.AND 2.0 1.0 1.9
Young MRL.AND 1.7 1.8 1.4
Older B10.AND 5.9 10.4 4.6
Older CBA.AND 3.3 5.3 6.8
Older MRL.AND 3.8 9.8 4.5
Flow cytometry was performed on CD41Va11hi T cells for the
activation markers CD69, CD25, CD44, and CD62L in both young (1–2
mo) and older (8–9 mo) AND TCR transgenic mice. Activated T cells
were defined as the CD44hi
 CD62Llo population (reference 15). Results
are representative of two separate experiments involving cohorts of two
to three transgenic animals from each group (MRL.AND, B10.AND,
and CBA.AND).
Figure 1. CD41 AND transgenic T cells from MRL mice proliferate more after agonist peptide and mitogenic stimulation than CD41 AND trans-
genic T cells from nonautoimmune strains. (A) Naive CD41 transgenic T cells were labeled with CFSE and stimulated with 0.05 mM PCC 88–104 ag-
onist peptide using CH27 cells as APCs. The number of cell divisions at 72 h was determined by CFSE labeling. CH27 and dead T cells were excluded
from the analysis on the basis of forward/side scatter. The mean number of cell divisions at 72 h is indicated in the bar graph at the right. *P , 0.005 for
comparison of MRL.AND to B10.AND or CBA.AND cells. Arrows indicate evidence of cell division. (B) Naive AND transgenic T cells were stimu-
lated in vitro by I-Ek bearing B7.11/B7.21 CH27 cells pulsed with varying concentrations of PCC 88–104. Proliferation was measured at 72 h by
[3H]thymidine incorporation. Results are means of quadruplicate measurements. Error bars represent SEM. *P , 0.05 for comparison of MRL.AND to
B10.AND or CBA.AND cells. (C) Naive AND transgenic T cells were stimulated in vitro with 10 ng/ml of PMA and 500 ng/ml of ionomycin. Prolif-
eration was measured at 72 h by [3H]thymidine incorporation. Results are means of quadruplicate measurements. *P , 0.05 for comparison of
MRL.AND to B10.AND or CBA.AND cells.333 Vratsanos et al.
could be due to decreased cell death as well as increased
proliferation of individual T cells. To address this question,
we studied the proliferative history of individual transgenic
T cells using CFSE labeling. This also allowed us to specif-
ically gate on CD41Va11hi TCR transgenic cells (16).
TCR transgenic cells stimulated with 25 mM APL K99Q
resulted in a significant increase in the mean number of cell
divisions in MRL.AND T cells at 72 h compared with
CBA.AND and B10.AND cells (Fig. 3 A). This concentra-
tion of K99Q was 50-fold higher than used to stimulate
cells with agonist peptide for cell division (Fig. 1 A). A
small fraction of control B10.AND and CBA.AND T cells
did undergo two to three rounds of cell division in re-
sponse to stimulation with APL K99Q. Likewise, a signifi-
cantly higher proportion of MRL.AND T cells proliferated
in response to stimulation with a 50-fold higher concentra-
tion (25 mM) of antagonist APL K99R compared with
control CBA.AND T cells (Fig. 3 B). In this latter case, the
probability of cell division is shown, as the mean number of
cell divisions in all groups was ,1. Although an increased
number of MRL.AND T cells, including cells that divided
and those that did not, were available for analysis in the
data shown in Fig. 3 A, staining of transgenic T cells with
PI demonstrated an identical percentage of live (PI-nega-
tive) cells among all three strains upon stimulation with
these APLs (data not shown). This finding argues against
enhanced cell survival as the reason for the comparative in-
crease in proliferation seen in MRL.AND T cells.
Figure 2. CD41 AND transgenic T cells from MRL mice proliferate more and differentially express activation markers in response to low affinity
TCR ligands compared with CD41 transgenic T cells from nonautoimmune mice. (A and B) Naive splenic CD41 transgenic T cells were stimulated
with varying concentrations of K99Q (A) or A96I (B) presented by I-Ek bearing B7.11/B7.21 CH27 cells. (C) Naive CD44loCD62Lhi AND transgenic
T cells from lymph nodes were stimulated with varying concentrations of K99R presented by CH27 cells. Proliferation was measured at 72 h by [3H]thy-
midine incorporation. Results are means of quadruplicate measurements. *P , 0.005 for comparison of MRL.AND to B10.AND or CBA.AND cells in
A–C. (D) Naive CD44loCD62Lhi splenic CD41 transgenic T cells were stimulated with 25 mM K99Q or 0.05 mM PCC 88–104 presented by CH27
cells. CD44 and CD62L expression were determined by flow cytometry 48 h after stimulation, with CD44hi cells designated as activated cells and
CD44hiCD62Llo cells as memory cells. Arrows indicate the population of activated T cells that have upregulated CD44.334 T Cell Activation in Lupus
MRL.AND T Cells Produce More IL-2 upon Stimulation
with Low Affinity APLs Than Nonautoimmune T Cells.
Only minimal, if any, IL-2 is produced when AND TCR
transgenic T cells encounter low affinity APL K99Q (13).
Given our observation of enhanced proliferation by MRL
T cells in response to TCR stimulation with such ligands,
we next examined IL-2 production in response to APL
stimulation. Production of higher amounts of IL-2 could
also be necessary for the clonal expansion of autoreactive T
cells observed in disease. Hence, we measured the produc-
tion of IL-2 in culture supernatants by indirect ELISA.
There was a clear increase in the production of IL-2 from
MRL T cells after stimulation with K99Q compared with
control T cells (Fig. 4 A). This was confirmed by intracel-
lular cytokine staining for IL-2 by TCR transgenic
CD41Va11hi T cells (Fig. 4 B).
Discussion
T cell tolerance to self-antigens is maintained in the pe-
riphery through the induction of anergy, partial activation,
or cell death (13, 23). Since antigens with a low affinity for
binding to TCRs induce T cell anergy (5, 24), it is logical
to posit that the interaction of self-reactive T cells with
peptides having a low affinity for TCRs should normally
result in peripheral tolerance rather than activation. We hy-
pothesized that naive CD41 T cells from mice with a ge-
netic predisposition to lupus would become more activated
Figure 3. (A) AND transgenic T cells labeled with CFSE and stimu-
lated in vitro with CH27 cells alone (pink line) or pulsed with either 5
mM (red line) or 25 mM (blue line) K99Q. Fluorescence of T cells cul-
tured without APCs is indicated in green with analysis performed at 96 h.
Arrows indicate evidence of cell division. The mean number of cell divi-
sions at 96 h is indicated in the bar graph at the right. *P , 0.005 for
comparison of MRL.AND to B10.AND or CBA.AND cells. The change
in scale used in MRL plot is indicative of the increased number of T cells.
CH27 and dead T cells were excluded from the analysis on the basis of
forward/side scatter. (B) AND transgenic T cells were labeled with CFSE
and stimulated with 25 mM antagonist K99R. Arrows indicate cell divi-
sion at 48 h. The probability of cell division is shown in the bar graph at
right. Error bar represents SEM. *P  ,  0.0001 for comparison of
MRL.AND to CBA.AND T cells.
Figure 4. MRL.AND transgenic T cells produce more IL-2 after stim-
ulation with APLs than control transgenic T cells. (A) Negatively selected
naive CD41 AND transgenic T cells were stimulated in vitro with vary-
ing concentrations of a low affinity APL of PCC 88–104 (K99Q) pre-
sented by CH27 cells. IL-2 was determined by indirect ELISA from cul-
ture supernatant 24 h after stimulation. Error bars represent SEM of
triplicate wells. *P , 0.05 for comparison of MRL.AND to control non-
autoimmune transgenic strains. (B) The percentage of transgenic cells
producing IL-2 was estimated using intracellular cytokine staining with
anti–IL-2 by gating on CD41Va11hi double-positive cells. *P , 0.05 for
comparison of MRL.AND T cells to CBA.AND and B10.AND T cells.335 Vratsanos et al.
compared with T cells with the identical TCR from non-
autoimmune control strains in response to presentation of
such antigens by APCs. Moreover, this phenotype could
contribute to the abrogation of peripheral T cell tolerance
in lupus, potentially leading to the polyclonal T cell activa-
tion characteristic of disease.
Indeed, we found that naive CD41 AND transgenic T
cells specific for PCC from the lupus-prone, Fas-intact
MRL background divided more than control transgenic T
cells when stimulated in vitro with the full agonist peptide
PCC 88–104. This phenotype was not strictly dependent
on proximal TCR signaling, as MRL T cells were still hy-
perresponsive even when TCR signaling was bypassed
with PMA and ionomycin. Perhaps of greater importance,
the difference between T cells from MRL mice and con-
trol strains was even more apparent using APLs of this
ligand having lower affinity for the transgenic TCR. MRL
T cells divided more and more readily entered the cell cy-
cle. In particular, they produced more IL-2 when stimu-
lated with a low affinity ligand that results in minimal IL-2
synthesis by nonautoimmune CD41 T cells, despite evi-
dence of equivalent TCR engagement (data not shown,
reference 13). While it is possible that the proliferative al-
terations we identified are a consequence of decreased cell
death, as has been reported for CD41 T cells from C57BL
mice congenic for lupus susceptibility loci (6, 25), the aug-
mented response of AND TCR transgenic T cells to the
antagonist peptide K99Q suggests an intrinsic T cell abnor-
mality, since this peptide does not induce AICD in control
backgrounds (13). In addition, equivalent survival was seen
among the three groups of transgenic T cells as determined
by concurrent staining with PI. Finally, the hyperrespon-
sive phenotype we have observed in AND transgenic T
cells was not attributable to aberrant cell function due to
the expression of the transgene itself, as TCR transgenic T
cells from all three strains failed to proliferate when cul-
tured without APCs, and .90% of the transgenic T cells in
vivo remained in the naive state in all older transgenic mice
studied.
We believe this is the first example demonstrating that
naive lupus T cells are hyperresponsive upon initial en-
counter with peptide antigen, and in particular, that lupus
T cells, compared with nonautoimmune controls, have a
lower threshold of activation or an exaggerated response to
antigens with a low affinity for TCR engagement. These
results imply that one of the forces driving the activation of
a/b T cells in lupus is a heightened response to self-anti-
gens, independent of the nature of the APCs and degree of
costimulation. Further evidence suggesting an intrinsic ab-
normality in lupus T cells comes from recent genetic stud-
ies in NZM mice that demonstrated a locus on chromo-
some 7 associated with CD41 T cell polyclonal activation,
enhanced proliferation to anti-CD3, and decreased AICD
(6, 25, 26). This genetic locus is necessary for the develop-
ment of fully penetrant immune-mediated renal disease in
C57BL/6 congenic mice, highlighting the pathologic con-
sequence of global T cell activation (6). This NZM locus
overlaps with the lupus susceptibility locus Lbw5, mapped
in an (NZB 3 NZW) F2 cross (27), the MRL locus lmb3,
associated with lymphadenopathy, splenomegaly, and anti-
DNA autoantibody production (28), and the MRL locus
Lrdm2 associated with renal disease (29). These findings
suggest the possibility that there is a gene(s) in all lupus-
prone mice that confers an intrinsic abnormality in T cells,
and taken together, are consistent with the evolving view
that excessive, unchecked T cell activation is necessary for
the development of systemic autoimmunity. Support for
this notion comes from the observations that mice with hy-
perproliferative CD41 T cells, due to targeted disruption
either of regulators of the cell cycle (30) or TGF-b signal-
ing (31), develop a phenotype very similar to human lupus,
with antibodies against native DNA and immune complex
glomerulonephritis. Studies in human lupus patients have
also suggested that there are abnormalities in lymphocyte
signaling (7, 8, 32, 33).
Identification of a lower threshold for activation in lupus
T cells does not preclude other intrinsic abnormalities in
the immune system from contributing to a predisposition
to autoimmunity, such as abnormalities in B cell (26, 33,
34) or APC function (35), or in clearance of immune com-
plexes (36). Rather, we would argue that the intrinsic T
cell defect we describe, in conjunction with other abnor-
malities in the immune system, would be sufficient to dis-
rupt autoreactive T cell tolerance in the periphery, and is
consistent with the polygenic susceptibility model for lupus
supported by strong experimental evidence (26, 37). While
it is possible that the abnormalities we have identified
herein are the result of strain differences in TCR stimula-
tion between the MRL and nonautoimmune backgrounds,
and not related to the lupus phenotype, our results never-
theless offer a logical explanation of the polyclonal T cell
reactivity in lupus. This question will be addressed by de-
termining if the differences in CD41 T cell responses we
identified are associated with lupus susceptibility loci.
Although the above observations are limited to in vitro
studies, experiments are underway to compare the activa-
tion and survival of both naive and memory transgenic T
cells in vivo. Indeed, preliminary work from our laboratory
suggests that T cells from lupus-prone mice survive much
better in vivo in response to peptide ligands with low TCR
affinity, compared with cells from nonautoimmune con-
trols, similar to our in vitro results. These cumulative data
suggest the possibility that self-peptides normally displayed
by MHC class II molecules in the periphery, and responsi-
ble for naive CD41 T cell survival and homeostasis in nor-
mal animals, lead to enhanced (polyclonal) activation of T
cells from lupus-prone mice compared with cells from
nonautoimmune animals (38–40). In addition, studies are
underway that begin to address the biochemical mechanism
for the defect described in lupus T cells. It will be impor-
tant to compare the AICD of transgenic T cells when stim-
ulated with peptides having both low and high affinity for
the TCR.
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